CONTENTS

Acknowledgments v

Preface vii

Contributors xiii

Value-Added eBook/PDA xvii

PART I: BASIC SCIENCE OF TUMOR ANTIGENS AND IMMUNE ACTIVATION

1 Biology of the Cancer Vaccine Immune Response 3
Michael A. Morse, Timothy M. Clay, and H. Kim Lyerly

2 The Rational Design of T-Cell Epitopes With Enhanced Immunogenicity 11
John Fikes

3 Identification of Tumor Antigens Using Subtraction and Microarrays 19
Jiangchun Xu

4 Tumor Antigen Discovery With T Cells 31
Paul F. Robbins

5 Targeting Viral Antigens for the Treatment of Malignancies 49
Gretchen L. Eiben, Diane M. Da Silva, Steven C. Fausch, Amanda M. Krier, I. Caroline Le Poole, Megan E. Papineau, Michael I. Nishimura, and W. Martin Kast

6 Immune Defects in Cancer 65
Dmitry Gabrilovich and Vladimir Pisarev

7 Escape of Tumors From the Immune System:
Role of the Transforming Growth Factor-β-Signaling Pathway 85
Gerard C. Blobe

PART II: GENERAL VACCINE AND IMMUNOTHERAPY STRATEGIES

8 Immune Adjuvants 99
Jory R. Baldridge, Susan Hand Zimmermann, and Sally P. Mossman

9 Heterologous Prime-Boost Vaccination in Tumor Immunotherapy 115
Michael J. Palmowski and Caroline Smith

10 Peptide-Based Vaccines 121
Carmen M. Berger, Keith L. Knutson, Lupe G. Salazar, Kathy Schiffman, and Mary L. Disis

11 Antibody-Inducing Cancer Vaccines
Against Cell-Surface Carbohydrate Antigens 137
Govind Ragupathi, John Gathuru, and Philip O. Livingston

12 Anti-Idiotype Vaccines 157
Sunil K. Chatterjee, Malaya Bhattacharya-Chatterjee, and Kenneth A. Foon

13 Pox Viral Vaccines 175
James L. Gulley, Philip M. Arlen, and Jeffrey Schlom

14 Utility of Adenovirus-Based Vectors for Multiple Cancer Vaccine Approaches 193
Zachary Hartman and Andrea Amalfitano

15 Alphaviral-Based Strategies for the Immunotherapy of Cancer 203
Edward L. Nelson and Jonathan Smith

16 DNA Vaccines 225
Michael Bereta and Howard L. Kaufman

17 Whole-Cell Vaccines 249
Timothy M. Clay, Paul J. Mosca, H. Kim Lyerly, and Michael A. Morse

18 Gene-Modified Tumor-Cell Vaccines 253
Leisha A. Emens and Elizabeth M. Jaffee

19 Hapten-Modified Tumor Vaccines 275
David Berd

20 Chaperone Proteins/Heat Shock Proteins As Anticancer Vaccines 297
Michael W. Graner and Emmanuel Katsanis

21 Dendritic Cell Vaccines 317
Madhav V. Dhodapkar

22 Exosomes for Immunotherapy of Cancer 331
Nathalie Chaput, N. E. C. Schartz, Fabrice Andre, and Laurence Zitvogel

23 Immunocytokines for Cancer Immunotherapy 341
Paul M. Sondel and Steven D. Gillies

24 T-Cell Adoptive Immunotherapy 359
Gregory E. Plautz, Peter A. Cohen, David E. Weng, and Suyu Shu

PART III: TUMOR-SPECIFIC VACCINE DEVELOPMENT

25 Melanoma Vaccines 379
Jeffrey Weber

26 Allogenic Melanoma Lysate Vaccines 397
Malcolm S. Mitchell

27 Renal Cancer Vaccines 415
Hyung L. Kim, Barbara J. Gitlitz, and Robert A. Figlin

28 Vaccines for Hematological Malignancies 425
Qing Yi

29 Vaccines for the Immunotherapy of Prostate Cancer 451
Boris Minev and Michael L. Salgaller

30 Vaccine Therapy for Breast and Ovarian Cancers 465
Susan E. Smith and Alison T. Stopeck

31 Vaccine Therapy for Gastrointestinal Cancers 491
John L. Marshall

32 Vaccines for Lung Cancer 505
Michael A. Morse, Jennifer Garst, and Eric Toloza

33 Vaccines for Other Tumors 513
Michael A. Morse

PART IV: CLINICAL TRIALS AND IMMUNE ANALYSES

34 Clinical Trial Designs for Therapeutic Vaccine Studies 519
Richard Simon

35 Analysis of Cellular Immune Responses in Cancer Vaccine Trials 527
Timothy M. Clay, Michael A. Morse, Paul J. Mosca, Amy Hobeika, Donna Niedzwiecki, and H. Kim Lyerly

36 Analysis of Humoral Immune Responses in Vaccine Trials 543
Rajasekharan Somasundaram, Tianqian Zhang, and Dorothee Herlyn

37 Regulatory Issues Affecting Tumor Vaccines 563
Mark O. Thornton, Alexandra S. Worobec, Keith Wonnacott, and Raj K. Puri

Index 577